pre-IPO PHARMA

COMPANY OVERVIEW

Viriom (San Diego, CA) focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to the best antiviral treatments. Viriom's broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV and viral hepatitis.


LOCATION

  • San Diego, CA, USA

  • THERAPEUTIC AREAS

  • Infectious Disease

  • WEBSITE

    https://www.viriom.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Mar 9, 2021

    Viriom and Chromis publish results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021


    May 4, 2020

    Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients


    Apr 8, 2020

    Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19


    Mar 24, 2020

    Viriom donates Elpida to Chinese and Russian governments for experimental use against COVID-19; also working with global health authorities to determine the efficacy and safety of Elpida and its other clinical candidates AV5080, AV5124 and AV5126 against COVID-19


    Dec 3, 2019

    Viriom Launches Reproductive Toxicity Studies for Elpida (Elsulfavirine) Once Weekly Oral Formulation


    For More Press Releases


    Google Analytics Alternative